Oncolytics Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Oncolytics Biotech
ONCY Stock  USD 0.93  0.02  2.11%   
Oncolytics Biotech financial statements provide useful quarterly and yearly information to potential Oncolytics Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncolytics Biotech financial statements helps investors assess Oncolytics Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncolytics Biotech's valuation are summarized below:
Market Capitalization
71.7 M
Earnings Share
(0.26)
We have found one hundred twenty available trending fundamental ratios for Oncolytics Biotech, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Oncolytics Biotech recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 137.3 M in 2024. Enterprise Value is likely to rise to about 118 M in 2024

Oncolytics Biotech Total Revenue

4.85 Million

Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Oncolytics Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.5 M38.8 M26.2 M
Slightly volatile
Total Current Liabilities3.9 M4.2 M4.6 M
Very volatile
Property Plant And Equipment Net460.6 K647 K498.4 K
Slightly volatile
Accounts Payable1 M1.1 M2.7 M
Slightly volatile
Cash19.4 M34.9 M20.7 M
Pretty Stable
Non Current Assets Total614.6 K647 K746 K
Very volatile
Cash And Short Term Investments26.6 M34.9 M23.3 M
Slightly volatile
Net Receivables14.2 K15 K616.2 K
Very volatile
Common Stock Shares Outstanding71 M67.6 M26.7 M
Slightly volatile
Liabilities And Stockholders Equity30.5 M38.8 M26.2 M
Slightly volatile
Other Current Assets3.4 M3.2 M1.4 M
Slightly volatile
Other Stockholder Equity38.1 M42.1 M29.4 M
Slightly volatile
Total Liabilities6 M11.3 M7.7 M
Slightly volatile
Total Current Assets28 M38.2 M25.3 M
Slightly volatile
Common Stock452.5 M430.9 M285.6 M
Slightly volatile
Property Plant Equipment377.8 K749.8 K474.7 K
Slightly volatile
Capital Surpluse29 M37.9 M23.2 M
Slightly volatile
Net Working Capital26.6 M33.9 M18.9 M
Slightly volatile
Capital Stock399.6 M430.9 M324 M
Slightly volatile

Oncolytics Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization77 K81 K1 M
Pretty Stable
Selling General Administrative16.9 M16.1 M7.4 M
Slightly volatile
Other Operating Expenses19.5 M33.8 M21.5 M
Pretty Stable
Research Development12.6 M17.7 M13.8 M
Pretty Stable
Total Operating Expenses19.1 M33.8 M21.5 M
Pretty Stable
Net Interest Income1.2 M1.2 M315.8 K
Slightly volatile
Interest Income1.2 M1.2 M315.8 K
Slightly volatile
Reconciled Depreciation370.4 K395 K224.2 K
Slightly volatile
Selling And Marketing Expenses18.9 M18 M3.9 M
Slightly volatile

Oncolytics Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.8 M11.7 M20.6 M
Very volatile
Other Cashflows From Financing Activities742 K781 K1.8 M
Slightly volatile
Depreciation300.3 K403 K233.8 K
Slightly volatile
Capital Expenditures7.6 K8 K103.6 K
Slightly volatile
Total Cash From Financing Activities18.9 M32 M19.2 M
Slightly volatile
End Period Cash Flow19.4 M34.9 M20.7 M
Pretty Stable
Stock Based Compensation1.5 M2.1 M1.4 M
Slightly volatile
Issuance Of Capital Stock27.7 M36.1 M18.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio66.8370.342.9 M
Slightly volatile
Days Sales Outstanding3.73.8914.0234
Slightly volatile
Average Payables325.5 K342.6 K2.4 M
Slightly volatile
Stock Based Compensation To Revenue0.120.140.1479
Slightly volatile
Capex To Depreciation0.01890.01991.5094
Slightly volatile
EV To Sales62.4865.762.6 M
Slightly volatile
Inventory Turnover127142155
Slightly volatile
Payables Turnover0.350.372526.9458
Pretty Stable
Sales General And Administrative To Revenue0.120.140.1479
Slightly volatile
Research And Ddevelopement To Revenue13.117.447.3417
Very volatile
Capex To Revenue0.02850.030.0352
Slightly volatile
Cash Per Share0.540.56621.9859
Slightly volatile
Days Payables Outstanding9319803.5 K
Pretty Stable
Income Quality0.711.02510.8951
Pretty Stable
Intangibles To Total Assets0.01410.01490.0361
Slightly volatile
Net Debt To EBITDA1.521.02311.4476
Slightly volatile
Current Ratio13.959.009410.3926
Pretty Stable
Receivables Turnover10297.0899.557
Slightly volatile
Graham Number1.841.946.5987
Slightly volatile
Debt To Equity0.0090.00560.0063
Slightly volatile
Capex Per Share1.0E-41.0E-40.0107
Slightly volatile
Graham Net Net0.380.39991.5518
Slightly volatile
Average Receivables66.7 K40.3 K70.7 K
Pretty Stable
Revenue Per Share0.570.550.5592
Slightly volatile
Interest Debt Per Share0.00990.01050.0249
Slightly volatile
Debt To Assets0.00840.00510.0059
Slightly volatile
Days Of Payables Outstanding9319803.5 K
Pretty Stable
Ebt Per Ebit0.80.81840.9804
Very volatile
Long Term Debt To Capitalization0.00890.00560.0063
Slightly volatile
Total Debt To Capitalization0.00890.00560.0063
Slightly volatile
Debt Equity Ratio0.0090.00560.0063
Slightly volatile
Quick Ratio13.929.009410.3906
Pretty Stable
Net Income Per E B T0.811.00351.005
Very volatile
Cash Ratio9.58.23989.1033
Slightly volatile
Days Of Sales Outstanding3.73.8914.0234
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00031.0162
Pretty Stable
Fixed Asset Turnover11.210.6710.9418
Slightly volatile
Debt Ratio0.00840.00510.0059
Slightly volatile
Price Sales Ratio66.8370.342.9 M
Slightly volatile
Asset Turnover0.210.20.2031
Slightly volatile
Operating Cycle2.73.053.3161
Slightly volatile

Oncolytics Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap137.3 M118.2 M117.4 M
Pretty Stable
Enterprise Value118 M83.7 M96.8 M
Pretty Stable

Oncolytics Fundamental Market Drivers

Cash And Short Term Investments34.9 M

Oncolytics Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-973.8 K-925.1 K
Cost Of Revenue403 K382.9 K
Stock Based Compensation To Revenue 0.14  0.12 
Sales General And Administrative To Revenue 0.14  0.12 
Research And Ddevelopement To Revenue 7.44  13.11 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.55  0.57 
Ebit Per Revenue(6.81)(7.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY